Literature DB >> 7485382

Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E.

W W Hancock1, M Polanski, J Zhang, N Blogg, H L Weiner.   

Abstract

Oral administration of autoantigens suppresses development of autoimmunity in several animal models, and is being tested in clinical trials in patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. Non-obese diabetic (NOD) mice spontaneously develop insulin-dependent diabetes mellitus at 15 to 20 weeks of age, after mononuclear cell (MNC) infiltration of the pancreatic islets of Langerhans and destruction of insulin-producing beta cells. We have previously shown that oral administration of insulin suppresses insulitis and development of diabetes in the NOD mouse. Oral insulin has no metabolic effect on blood glucose. Oral insulin mediates its effect through a T cell-dependent mechanism as shown by adoptive transfer and T cell depletion experiments, but the mechanisms responsible have not been fully explored. We now report a serial analysis of the cells and cytokines associated with development of diabetes in NOD mice, and contrast this with the findings in animals fed equine insulin or a control protein (ovalbumin). Animals were fed 1 mg twice a week for 5 weeks, beginning at 5 weeks of age. Marked insulitis in naive or ovalbumin-fed NOD mice occurred at 10 weeks, at which time a dense peri-islet and intra-islet MNC infiltration was observed. Immunohistological studies using monoclonal antibodies showed that infiltrating MNC consisted mainly of CD4+ T cells ( > 75% of leukocytes) plus smaller numbers of macrophages and CD8+ T cells. These cells displayed evidence of immune activation with expression of receptors for interleukin-2 (IL-2R) plus Th1 cytokines; dense labeling for IFN-gamma and tumor necrosis factor-alpha, plus lesser amounts of IL-2, was observed. MNC lacked labeling for IL-4, IL-10, prostaglandin-E, or transforming growth factor-beta. By contrast, at 10 weeks, pancreatic tissues from NOD mice fed insulin showed considerably less insulitis, and the residual MNC, although still largely CD4+ T cells plus macrophages, showed dense labeling for IL-4, IL-10, prostaglandin-E, and transforming growth factor-beta and an absence of IL-2, IFN-gamma or tumor necrosis factor-alpha Taken together with our previous findings, these data indicate that oral administration of insulin affects the development of diabetes in NOD mice through the generation of cells that elaborate immunoregulatory cytokines within the target organ and shift the balance from a Th1 to a Th2 pattern of cytokine expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485382      PMCID: PMC1869521     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  17 in total

Review 1.  Islet cell autoantigens in insulin-dependent diabetes.

Authors:  M A Atkinson; N K Maclaren
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

2.  Altered cytokine activity in adjuvant inhibition of autoimmune diabetes.

Authors:  N N Shehadeh; F LaRosa; K J Lafferty
Journal:  J Autoimmun       Date:  1993-06       Impact factor: 7.094

3.  Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy.

Authors:  P L Mottram; W R Han; L J Purcell; I F McKenzie; W W Hancock
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

4.  Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse.

Authors:  K J Pennline; E Roque-Gaffney; M Monahan
Journal:  Clin Immunol Immunopathol       Date:  1994-05

Review 5.  Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation?

Authors:  A Rabinovitch
Journal:  Diabetes       Date:  1994-05       Impact factor: 9.461

6.  Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes.

Authors:  F G Snijdewint; P Kaliński; E A Wierenga; J D Bos; M L Kapsenberg
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

7.  Epitopes of myelin basic protein that trigger TGF-beta release after oral tolerization are distinct from encephalitogenic epitopes and mediate epitope-driven bystander suppression.

Authors:  A Miller; A al-Sabbagh; L M Santos; M P Das; H L Weiner
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

8.  CD8 T cells are not required for islet destruction induced by a CD4+ islet-specific T-cell clone.

Authors:  B J Bradley; K Haskins; F G La Rosa; K J Lafferty
Journal:  Diabetes       Date:  1992-12       Impact factor: 9.461

9.  Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function.

Authors:  R A Daynes; B A Araneo; T A Dowell; K Huang; D Dudley
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

10.  Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice.

Authors:  M J Rapoport; A Jaramillo; D Zipris; A H Lazarus; D V Serreze; E H Leiter; P Cyopick; J S Danska; T L Delovitch
Journal:  J Exp Med       Date:  1993-07-01       Impact factor: 14.307

View more
  35 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease.

Authors:  S T Azar; H Tamim; H N Beyhum; M Z Habbal; W Y Almawi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 4.  Oral tolerance and gut-oriented immune response to dietary proteins.

Authors:  O Alpan
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

Review 5.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

Authors:  Lucienne Chatenoud
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

7.  Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice.

Authors:  D G Karounos; J S Bryson; D A Cohen
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

8.  The pathogenicity of islet-infiltrating lymphocytes in the non-obese diabetic (NOD) mouse.

Authors:  V Ablamunits; D Elias; I R Cohen
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

9.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  Pathogenicity of T helper 2 T-cell clones from T-cell receptor transgenic non-obese diabetic mice is determined by tumour necrosis factor-alpha.

Authors:  Jing He; Kathryn Haskins
Journal:  Immunology       Date:  2007-11-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.